Next DTP-22-013, production of TAK-243 injectable for clinical use and study the shelf-life. Contract/to#dctc-2022-1006, development & manufacture of oral & topical dosage forms - PRB
Ended Awarded Last action
- Contract number
- 75N91022F00003
- Awardee
-
Societal Cdmo San Diego, LLC UEI YRPTVKHDL7Z5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $620,051
Award facts
- Opportunity
-
- TORFP20221006 Solicitation number
- Contract value 100% obligated
- $620,051.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- Q517 Pharmacy Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$72,000 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $52,900 | |
| Supplemental Agreement for work within scope | $130,000 | |
| Original award | $509,151 |
About this award
This is a $620,051 delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The contract is for the production of TAK-243 injectable for clinical use and study of its shelf-life. Societal CDMO will also develop and manufacture oral and topical dosage forms under this delivery order. This contract is issued under the $45 million Drug Formulation and Manufacturing Contracts 2019 indefinite delivery, indefinite quantity (IDIQ) vehicle, which provides product development and manufacturing services to NIH and other HHS components like the National Center for Advancing Translational Sciences and National Institute on Drug Abuse. Societal CDMO has previously held task orders under this and other IDIQ contracts with HHS and the Department of Veterans Affairs to support their translational research and clinical studies across oncology, neurology, addiction, and rare diseases.
Quick answers
Who was awarded contract 75N91022F00003?
75N91022F00003 was awarded to Societal Cdmo San Diego, LLC by National Cancer Institute (National Institutes of Health) on April 11, 2022.
How much is contract 75N91022F00003 worth?
The government has obligated $620,051 on 75N91022F00003.
Is contract 75N91022F00003 an order under another contract?
Yes. 75N91022F00003 is a delivery order under 75N98019D00058, an indefinite delivery contract, on Drug Formulation and Manufacturing Contracts 2019.
Was contract 75N91022F00003 competed?
The extent of competition for 75N91022F00003 was full and open competition after exclusion of sources. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award